Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Lineage Cell Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 100 | 1 | 104 | +5 |
| Shares | 65.0M | 10.0K | 64.7M | −260.2K (−0.4%) |
| Value | $102.7M | $16.0K | $73.1M | −$29.5M (−28.8%) |
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (16)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jacobs Levy Equity Management, Inc | 257,461 | $291.0K | 0.00% |
| Lazard Asset Management LLC | 77,974 | $88.0K | 0.00% |
| Public Employees Retirement System of Ohio | 45,623 | $52.0K | 0.00% |
| Marshall Wace, LLP | 43,827 | $50.0K | 0.00% |
| Thrivent Financial for Lutherans | 15,000 | $17.0K | 0.00% |
| Mariner, LLC | 14,227 | $16.0K | 0.00% |
| Haverford Trust Co | 13,612 | $15.0K | 0.00% |
| ELCO Management Co., LLC | 12,000 | $14.0K | 0.01% |
| Prelude Capital Management, LLC | 11,465 | $13.0K | 0.00% |
| USAdvisors Wealth Management, LLC | 10,869 | $12.0K | 0.01% |
| Barclays PLC | 7,637 | $9.00K | 0.00% |
| Wipfli Financial Advisors LLC, | 5,000 | $6.00K | 0.00% |
| BNP Paribas Arbitrage, SA | 4,209 | $4.76K | 0.00% |
| Trust Co of Vermont | 2,079 | $2.00K | 0.00% |
| 1832 Asset Management L.P. | 5 | $0 | 0.00% |
| Trustcore Financial Services, LLC | 142 | $0 | 0.00% |
Sold out (11)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Y-Intercept (Hong Kong) Ltd | 44,829 | $71.0K |
| Boothbay Fund Management, LLC | 27,777 | $44.0K |
| Morgan Jess S & Co Inc | 20,000 | $32.0K |
| D. E. Shaw & Co., Inc. | 10,886 | $17.0K |
| Balyasny Asset Management LLC | 10,432 | $16.0K |
| Integrated Wealth Concepts LLC | 10,000 | $16.0K |
| Concord Wealth Partners | 1,500 | $2.00K |
| New York State Common Retirement Fund | 907 | $1.00K |
| Proffitt & Goodson Inc | 17 | $0 |
| Capital Advisors, Ltd. LLC | 38 | $0 |
| Curi Capital | 51 | $0 |
Not filed for Q3 2022 yet (1)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Quadrant Private Wealth Management, LLC | 10,000 | $16.0K |